Tevogen Bio Holdings Inc. Warrant

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced its 2026 Annual Meeting of Stockholders scheduled for August 24, 2026, to be held virtually. The company has set July 23, 2026 as the record date for stockholders and the deadline for submitting stockholder proposals and director nominations. Tevogen continues to focus on its three complementary ...

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has signed a non-binding Letter of Intent to evaluate acquiring a Management Services Organization (MSO). If completed, the transaction could expand Tevogen's healthcare infrastructure and support its evolution into a revenue-generating enterprise with combined annual revenue of approximately ...

Tevogen Bio Holdings Inc. announced capital discipline measures including its lead investor Dr. Manmohan Patel's commitment to maintain shareholdings, a pledge to limit share utilization to 1% of authorized shares over the next 12 months or until cash-flow positive, and evaluation of acquisitions that could generate over $50 million in combined a...

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced progress on TVGN 489, its investigational T-cell therapy for Long COVID, following the appointment of a new leadership team on March 9, 2026. The company expanded HLA target coverage to reach 65% of the U.S. population and is evaluating the acquisition of Sciometrix's Clinicus platform for real-w...

Tevogen Bio Holdings (NASDAQ:TVGN) announced a non-binding Letter of Intent to explore acquiring Apozeal Pharmaceutical Inc. to strengthen its generics platform and enhance pharmaceutical affordability. The stock surged to $10.8 before falling, and is now trading at a 52-week low of $6.56, down 15.41% on the day. The company also approved a 50-fo...